Home/Pipeline/INDP-101

INDP-101

Advanced Solid Tumors

Phase 1Active, not recruitingNCT05958935

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1

Status

Active, not recruiting

Company

Indaptus Therapeutics

About Indaptus Therapeutics

Indaptus Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for oncology and virology through its proprietary Decoy platform. The company's lead candidate, INDP-101, is in clinical trials for advanced solid tumors, designed to stimulate both innate and adaptive immunity. Its strategy centers on leveraging this multi-pathway approach to potentially enhance the efficacy of existing immunotherapies and address significant unmet medical needs in treatment-resistant cancers.

View full company profile

Therapeutic Areas

Oncology Virology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
NST-101 (estimated)	Novastage Pharmaceuticals	Phase 1/2	Active
Meta10-TILs	Leman Biotech	Phase 1	Active (Investigator-Initiated Trial)
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
P-002	Panacea Biotec	Phase 1/2	Active
Undisclosed kinase inhibitor	Tyligand Bioscience	Phase 1	Active
TYK-001	TYK Medicines	Phase 1/2	Active
PT-112	SciClone Pharmaceuticals	Phase 1	Active - Subject Recruitment
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BP1001-A	Bio-Path Holdings	Phase 1	Active